## Index

Abbott Laboratories 457–458  
Abbreviated New Drug Application (ANDA) 455  
abstract ideas unpatentable 46, 52  
abusive filing of IP rights  
    blocking patents 476–480, 481  
    finding abuse a rare exception 479–480  
    fraudulent patents 470–476, 478  
    inequitable conduct 468–469  
    objective nature of the abuse 473–474  
    registration of IP rights 468, 472–473  
    relevance of competition law 469, 480–481  
access to data and material transfer agreements  
    Brazil 342  
    could serve as contractual substitutes for patenting 260  
    downstream effects 285–289  
    models facilitating 312  
    secrecy and delays in dissemination of genetic research results 266, 267–268  
    upstream effects 280–284  
    see also material transfer agreements (MTAs); patent clearinghouses; patent pools; Standard Material Transfer Agreement (SMTA)  
access to genetic resources and benefit-sharing (ABS) 198, 201–205, 207, 208–209  
access to medicine see compulsory licenses; generic drugs; medicine  
access window for biologic originators 115  
Actavis (AndroGel case) 457–459  
active drug moiety 106  
active pharmaceutical ingredients (API) 410–411, 420, 422  
Actos (diabetes drug) 458–459  
Adriaan de Peijper case 442  
adult stem cells, definition 244–245  
Advanced Building Systems Pty Limited v. Ramset Fasteners (Aust) Pty. Limited 97  
advancement of knowledge vs. commercial exploitation 235, 236, 241  
AgAccord 192, 194–196  
The Age 92  
Agreement of the Unified Patent Court (UPC) 155  
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)  
alternative to TPP for exclusivity 115  
    compulsory licenses as TRIPS flexibility 424–425, 427–429  
dissatisfaction of developing countries with 369–372  
India conforming differently to TRIPS agreement 372–379  
Kenyan compliance with 395, 396–398  
national needs vs. harmonization 99–100  
    patent reform in Brazil and 337, 342, 343, 345, 346, 347–348, 349  
    pharmaceutical vs. farmers’ lobby 370  
    plant exceptions from patentability 137–138  
    protection of plant varieties required 121, 206  
    protection of undisclosed information in regard to imported soy meal patent protection 183–184  
    requirements for patents 470, 478  
    uncertainty regarding arbitral panel jurisdiction 424, 432–436  
    UPOV definition of variety vs. 122  
    see also competition; Doha Declaration on the TRIPS Agreement and Public Health; health  
agriculture as biggest driver of biodiversity loss 198–199  
e-licensing platforms 321–322  
patent clearinghouses 318–319  
    see also farmers  
agro-biodiversity conservation, plant IP and 198–199  
AIDS see HIV/AIDS  
Alice Corp. v. CLS Bank Int’l. 23, 27–28, 38, 52, 53, 92–93  
Allsop, James 96–97  
Alumnia, Joaquin 467  
American Association for Molecular Pathology (AMP) 20  
American Civil Liberties Union (ACLU), challenge to Constitutionality of gene patents 20  
American Seed Trade Association (ASTA) 194–196  
Amgen, Inc. v. Chugai Pharmaceuticals Co. 47  
isolated sequence non-patentable 151
no impact of TPP on pharmaceutical law 115
patent examination guidelines 77–84
patent practice regarding diagnostic methods 25
Plain Packing Act 431
see also D’Arcy v. Myriad Genetics, Inc.
background IP 293, 295–296, 301, 303
barriers to entry 192, 269
Barter, Krystal 100
Bayer Inc., Nexavar licence 374
Bayer v. Cipla 377, 457
Beijing Double-Crane Pharmaceutical Co. v. Xiangbei Welman Pharmaceutical Co., Ltd. and the Patent Reexamination Board of the SIPO 365–367
benefit-sharing mechanisms 208–210, 213
see also access to genetic resources and benefit-sharing (ABS)
Bergstrom case 393
best mode of invention execution
Brazil 340, 341, 345, 347, 349, 353
South Africa 416
bilateral agreements, Brazil’s Patent Prosecution Highways 351–352
bilateral investment treaties (BITs) 429–430, 432, 433
bilateral licenses favored over collaborative licensing 331
Bilski v. Kappos 18, 42
biodiversity see plant genetic resources
bio-generics see follow-on biologics
Biological Materials Transfer (BMT) Project 319–320, 323
Biologic License Applications (BLAs) 107, 110
biologics/biologicals
12-year exclusivity in US 110–112
Biologics Price Competition and Innovation Act (BPCIA) 107–108
concern regarding IP protection under TPP 101–103
definitions 104–105
FDA Purple Book 108
TPP provisions 113–116
uncertainty 116–117
see also biosimilars; follow-on biologics
biomarker-based diagnostic tests 16–17, 24
biopiracy, ABS restrictions to prevent 206
biosimilars
definitions 3–7, 104–105
EPO leading cases 10–11
interchangeable status 10
requirements under Swiss patent law 7–10
Sandoz application for Zarxio 109–110
US approach 12–14, 107
biotechnology, rise and fall of US patents 41–43, 275–276
Biotechnology Directive 98/44/EC
breeder’s exemption 155–156, 223–225
compulsory licenses 223–224
EC statement on exclusions from 214
EPC on description of inventions vs. 217–218
exhaustion of rights 221–222, 445–446
farmers’ privilege 222
patentability of imported soy meal patent protection 183–184
patent-eligibility of isolated human DNA sequences 27, 29–32, 33, 35–36, 39
plant progeny claims 152–153
question of revising 158–159
scope of protection of native traits 146, 215, 218–220, 224–225
Biotechnology Industry Organization (BIO) 101, 194–196
BIO Ventures for Global Health (BVGH) 317–318
Biwott, Nicholas 397, 398
‘blind spots’ addressed by judges 406
block exemption regulations 449–450
blocking patents
checks on 249
competition law and 476–481
facilitating access to 323–324, 332
innovation and 277, 278
patent thickets vs. 269
potential effect of gene patents 310
practical exclusion as problem of 280
as private firm strategy 267
risk of blocking positions 324, 465
Boehringer case 476–477
Bonynthon, Wendy 80
Bowman v. Monsanto Co. 186, 190
Brazil
Abifina 338, 345, 354
Competition Agency (CADE) 347, 350, 351
compulsory licenses 350–351
Congress, patent recommendations to 340, 342, 343, 346, 349, 350
Council of Intellectual Property Rights (CODIPI) 353–354
Inter-Ministerial Group on IP (GIPI) 347, 348, 349, 351, 352, 353–354
Ministry of Health 344, 350–351
Biotechnology, Technology and Innovation 342
Ministry of Science, Technology and Innovation 342
National Health System 345
need for patent reform 337–339, 354
new forms of known substances and new uses 345–347
non-extension of the patent term 342–343
patentability requirements and patent quality 339–341
patent backlog and patent quality 352–353
Patent Prosecution Highways (PPHs) 351–352
pipeline patents (revalidation patents) 344–345
pre-grant opposition 341–342
public non-commercial use 343
Sanitary Agency (Anvisa) 341, 346, 347–349, 350
undisclosed test data protection 349–350
Brazil – Retreaded Tyres case 429
BRCA genes and testing
description over patents 304
description 19–20
European patent actions 21, 98
US patent actions 20–21, 49–53, 90–91, 93, 232
breast cancer see cancer
breeder’s exemption 129, 154–156, 164, 208, 223–225, 447
breeding technologies of plants
background 133
breeding method as claiming strategy 163
extension of claims to plants and progenies 153–154
goal of obtaining improved phenotype 132
IP requirements as breeding objective 199
natural products and 176
no longer unpredictable 142–143
technology development 197
see also native traits, plants with; non-transgenic plants, EU patenting
Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc. 167–172
Bristol-Myers Squibb v Paranova A/S 448–449
Broccoli and Tomato cases 132–133, 138, 139–146, 148, 150, 158, 161, 214–216, 224
Browne, In re case 176
Brown, Sherrod 112
Brüstle v. Greenpeace 229–232, 235, 239
Bt event, definition 179
Budapest Treaty 136, 148, 149

Index 485

Duncan Matthews and Herbert Zech - 9781783479450
Downloaded from Elgar Online at 06/08/2019 02:48:23PM
via free access
Burk, Dan 283–284, 291
Busquin, Philippe 233–234
Calabresi, G. 327
California Institute for Regenerative Medicine 248
Canada
exclusivity provisions 113
gene patent approaches compared with 
Australia 94–96
Ontario threatened by Myriad Genetics 94
public non-commercial use 343
Canada, Supreme Court 187–189
Cànaves, Jaume M. 18
cancer
docetaxel 348
Herceptin™ treatment 16
licensing of anti-cancer drugs in Thailand 
425, 426
patents owned by Myriad Genetics 17
see also BRCA genes and testing; D’Arcy,
Yvonne
Cancer Council Australia 80–81
Cancer Voices Australia 60–61
Cancer Voices Australia v. Myriad Genetics, 
Inc. 56–58, 87
candor and good faith see good faith principle
Canola/rapeseed 174–175, 187–189
capital control policy of Japan 382
Carbone, Julia 94, 98
Celera 280–281, 283, 285–288
cell-free fetal DNA (cffDNA) 22–24, 53–54
Cephalon Inc. 460
chemical compounds 5, 9–10, 26, 29–30, 72,
165–168, 385, 389, 392
see also compound preparation, standard of 
creativity
Chiarolla, Claudio 212
Children’s Hospital of Eastern Ontario 
(CHEO) 95–96
China, IP protection in the life sciences
attitudes of the Chinese judiciary 356,
367–368
disclosure requirements in biotechnology
patents 361–363
legal framework 357–359
non-patentable subject matters 357–359
patentable subject matters 359–360
public non-commercial use 343
China State Intellectual Property Office (SIPO)
growth in biotechnology patent applications 
356
Guidelines for Patent Examination 354,
357–360, 361
Patent Reexamination Board 362, 364
China Supreme Court, ruling on new uses 364
Cipla 378
ciprofloxacin (Cipro) 457
cisgenic plants, definition 133
citalopram 460
citation analysis 270–271, 288–289
citation lags 272–274
claim definiteness requirement for patents 
254–255
claiming strategies for plant variety patents 
162–163
clearinghouses see patent clearinghouses
Clinical Oncology Society 80–81
clinical trials prerequisite to obtaining 
marketing authorization 300
collaborative licensing mechanisms
can transform property rules into liability
rules 327–329
effect on innovation 329–331
management structures 325–326, 332
market driven vs. policy driven models 324,
327
new objectives and modes of collaboration 
332
preventing patent fragmentation 306
sharing platforms vs. 333
Collins, Francis 286
corporate exploitation vs. advancement of
knowledge vs. 235, 236, 241
commercialization
Japan 383, 390
of university research 262–265, 267–268
US 264, 383
see also industrial applicability
commercial success as factor in examination of 
inventiveness 367
Commissioner of Patents, response to 
Australian High Court decision 79–80, 
82
Commissioner of Patents v. Microcell Ltd. 63
communication, researcher use of scientific
literature vs. patent record 271
compensation
for devaluation of patents by compulsory 
licenses 427, 434
in international invention arbitration 
435–436
in TRIPS vs. international investment 
arbitration 435–436
for use of plant varieties 130–131
see also Data Use and Compensation
Agreement (DUCA); equity and 
fairness; pay for delay agreements
competition
related TRIPS flexibilities 420–422
Index 487

by substitution rather than by imitation 479–480
competition law
  balancing patent law with 466–467, 472–473, 480–481
  collaborative licensing mechanisms and 326–327
  control of blocking patents 476–481
  EU’s seven conditions for patent pools 326
  Hatch-Waxman and Sherman Acts 454–455
  relevance 469
  research restrictions and 301
  TFEU restrictions 455–456
  unfair competition law 475–478
see also pay for delay agreements
complementary DNA (cDNA)
  definition 45
  Myriad’s patent 77
  need for clarification 83
  patentability 20, 49–50, 58, 90, 252, 305
  patentability of primers vs. 54–55
  composition of matter claims 15
  compound preparation, standard of creativity 365–367
compulsory licenses
  Biotechnology Directive 156, 157, 223–224
  Brazil 350–351
  European national legislation and case law 24–25, 36
  excluded from trademark law 478
  India 375–376
  international law 427–432, 436
  remedy to blocking effect 480
  South Africa 417–420, 421
  Thailand 424–427
  WTO law and ISDS 432–436
computer programs, patentability in Japan 388
confidentiality in R&D agreements
consent vs. notification in FP7 guide 236–237
Consten and Grundig v. Commission 441
consumer protection as central concern in pay for delay policy 466–467
contamination/infringement of transgenic plant patents 187–192
contract products/technologies, licenses to produce/distribute 301–303
contract research, research cooperation vs. 293–298, 301
contractual restrictions on parallel imports 449–450
Coordinated Framework (USDA, EPA, FDA) 192–193
copyrights 300, 353, 443
corn, patenting of non-transgenic varieties
  claims to the use of claimed inbred as parent variety 175–176
  current US practices 161–165
  patents vulnerable to challenge 177–178
  silence regarding the unexpected 171, 172
counterfeit drug imports see anti-counterfeit measures
Court of Justice of the European Union (CJEU)
  attempts at uniformity vs. European Court of Human Rights 231
  on concept of abuse in competition law 474
  exhaustion of rights case law 443–444
  first cases in relation to IP rights 441–442
  on patentability of imported soy meal 183–184
  potential impact of rulings 38–40
  re-packaging conditions 448–449
creativity see inventiveness requirement
Cresco/Taste of Nature dispute 147
CRISPR gene-editing technology 77
crop diversity 199, 205–207
see also plant genetic resources
Cubist Pharmaceutical Company 364
Customs Action against Goods Suspected of Infringing (EC Regulation) 439
Daptomycin case 364–365
D’Arcy, Yvonne 56–60, 79, 100, 102
D’Arcy v. Myriad Genetics, Inc.
  Federal Court debate on Myriad 56–58, 60–63
  High Court debate 21–22, 58–60, 64–74, 76, 88–89, 92–95, 97–98, 100
  manner of manufacture requirement 21–22
  new examination guidelines following 77–84
  significance of High Court’s Myriad ruling 100–103
Dastanab, pressure on India to license 376
data access agreements see access to data and material transfer agreements; material transfer agreements (MTAs)
data exclusivity see exclusivity
Data Use and Compensation Agreement (DUCA) 195
DeAngelis, Kathryn L. 275–279
Declaration on Regulatory Sovereignty Under TRIPS 379
defensive strategy of private firms 267
Delhi High Court 377
dematerialization of genetic resources 197–198, 208–210
denomination, plant variety 126
Dent, Chris 65
deoxyribonucleic acid (DNA) see cell-free fetal DNA (cfIDNA); complementary DNA (cDNA); DNA patents; DNA sequences
derived nucleotide sequences see DNA sequences
Dessi, SS 241
Deuel case 386
Deutsche Grammophon v. Metro 442–443
developing countries concern for public health and food security issues 370–372, 424–427 harvested materials and 221 diagnostics, patenting
access to genetic tests 310 fears and concerns 15–17 methods for diagnosing and treating farm animals in China 360 outlook 24–25 restricted access to materials 281 strengthening of patentability requirements 42 US approach compared to Europe and Australia 17–25 see also BRCA genes and testing; Mayo Collaborative Services v. Prometheus Laboratories Inc.
Diamond v. Chakrabarty 27–28, 36, 41, 46, 74, 91, 263, 385, 393
digital information see dematerialization of genetic resources Di Natale, Richard 87
discovery see inventiveness requirement; non-obviousness dispute resolution scheme, Biosimilars Act 12–14 distinctness of plant varieties 123–124 Dixon, Rosalind 406 DNA patents largest holders of 283 non-coding DNA and genomic mapping 78 see also cell-free fetal DNA (cfIDNA); complementary DNA (cDNA); diagnostics, patenting; human genes, patenting DNA sequences carving out human genes from patent protection 252, 304–305 as ‘discovery’ or ‘invention’ 360 inventions described by 133–134 isolated by introns not patentable 182 more than 40,000 related US patents 47 in native trait claims 150, 151 patentability 26, 29–35, 359, 388–389, 393 patent rights under Biotech Directive 183–184 plant-breeding claims 137 reproduction of naturally occurring 220 in Swiss patent claims 7–8 technology of 43–45 in transgenic and cisgenic plants 133–134 see also expressed sequence tags (ESTs)
Eli Lilly v. HGS 238–239

embryonic stem cells (ESC) 232, 244, 246, 247–249, 251–255

see also human embryonic stem cells (hESC); stem cell research

enablement requirement 174–175, 389–392
entirely vs. essentially 140–141
entrepreneurial route to commercializing research 264
Enza Zaden platform 322, 324, 325, 334

equity and fairness
access to medicine 371
equitable remuneration for inventors 164, 338
FET standard 430–432, 434–435
in health care access 81
inequitable conduct 463–464, 468–469
inequitable remuneration in patent pools 222, 313
in market access 372
unfair competition law 475–476
in use of genetic resources 83, 197, 199, 201, 205, 207, 212–213
equivalent effect measures 440–441
equivalents can indicate lack of inventive step 11
essentiality 309, 326–327
essentially biological processes 136, 139–146
essentially derived varieties 128–129
ethics
China’s caution regarding life science patents 356, 358, 360
of DNA patents 26, 42, 84–88
EPC morality clause 34–35
immoral invention exclusion in Japan vs. US utility requirement 390–391
life before profit 397
patent exclusions for use of human embryos 239
patent exclusions to protect public morality 185
of stem cell research 229–231, 245, 246, 254, 358
EU–Canada Comprehensive Economic and Trade Agreement (CETA) 115
EU Commission
fact specificity of patent settlements 466
few patent settlements pursued 467
on pay for delay agreements 451–454, 459–462
Technology Transfer Guidelines 465
see also Pharmaceutical Sector Inquiry/Pharma Sector Inquiry
Europe
cases vs. Myriad Genetics 21
Community Code Relating to Medicinal Products for Human Use 112
Community Plant Variety Regulation (CPVR) 122, 123–124, 130, 131, 445–447
Community Trademark Regulation (CTMR) 447–449
DNA patents influenced by USPTO 27–28
influence of US and Australian decisions 38–39
patentability of diagnostic methods 24–25
patent practice regarding diagnostic methods 25
United Patent Court (UPCA) 29, 39
European Court of Human Rights, CJEU’s attempts at uniformity vs. 231
European Free Trade Association (EFTA), international exhaustion of rights in a trademark 448
European Patent Convention (EPC)
Biotech Directive and 33, 35, 153, 217–218
controversial interpretations 214–215
exhaustion of rights 444–445
invention description required 147–148, 470
plant patentability 137–142, 182
question of revising 158–159
substantive conditions 470
UK membership left out Australia 99–100
European Patent Office (EPO)
citing deposited materials in claims 218
Enlarged Board of Appeal (EBA) 132, 138–141, 143–146, 148–150, 158, 214, 218
fragmentation of system post-grant 233
Myriad patents 21
not bound by EU law 158
patent-eligibility of isolated human DNA sequences 32–35
patents granted according to EPC 29
plant patents 214–218
restriction of genetic testing patents 98
Technical Boards of Appeal (TBA) 132, 142–144, 148
uncertainty regarding biosimilar patent applications 10–11
European Patent Package 29
European Research Area (ERA) 233–234
European Seed Associations see PINTO database
European Union (EU)
case law regarding pay for delay agreements 460–462
case study of NEUROSTEMCELL project 240–241
Community Code Relating to Medicinal Products for Human Use, 112, 300
competition law 326–327
countries empowered to ban transgenic crops 193
EC Treaty on free movement of goods 440–443
evolution of EU funded programs 232–234
 exclusivity same for biologics and small molecule medicines 112
gene patent approaches compared with Australia 96–98
IP law in EU vs. US 475–476
management and protection of IP 234–240
market and data exclusivity 300
stem cell research 229–232, 235, 239, 240–241
Trademark Directive 477–478
triple lock in EU policy on IPRs 241–242
unfair competition law 475–476
see also Biotechnology Directive 98/44/EC; Court of Justice of the European Union (CJEU); non-transgenic plants, EU patenting; parallel imports; Treaty on the Functioning of the European Union (TFEU)

European Union Framework Programme
First Framework Programme (FP1) 232–233
7th Framework Programme (FP7) 234–240
evergreening see stacking/evergreening
 exclusivity
 after patent expiration for transgenic plants 192–196
 for biologics 110–113
data and market exclusivity 106–107, 299–302
of diagnostic patents 15–17
patent pools/clearinghouses and 327–328
pay for delay agreements and 454–455, 463–465
rights provided by IP law 479
for small molecule medicines in the US 105–107
of test data attempted by pharmaceutical industry 349–350
TPP provisions and alternatives 115–116
exhaustion of rights
under Biotech Directive 221–222, 445–446
under CPVR 446–447
EU provisions 143–148
India 377–378
initial authorized sale limit of US patents 185–186
Kenya 397–399
parallel imports and 442–448

plant variety protection 130–131
South Africa 416–417
transgenic plants 185–186
expressed sequence tags (ESTs) 41, 47, 255, 385–386
expropriation 430–431, 433–434

Fabrizio, Kiria R. 272–274
fair and equitable treatment (FET) 430–432, 434–435
fairness see equity and fairness
farmers
farmers’ privilege 129–130, 222, 447
information needs 209–210
lobby vs. pharmaceutical lobby on TRIPS 370
rights under PGRFA 210–211
see also agriculture
Federal Court of Australia see Australia
fentanyl 461
fetal stem cells, definition 245
filing strategies, views on concurrent protection 163–165
follow-on biologics 4, 104
see also biologics/biologicals; biosimilars
food security
access to germplasm from 64 crops 207
developing country concerns with TRIPS 370–372
need for access to plant variation 311
plant IP and 198–199, 205–206
foreground IP
exploiting 301–303
FP7 stipulations 237, 238, 239
ownership 296–300, 303
fragmentation
of essential patents 309, 323–324, 331
patent overlap vs. 309–310
France, breeder’s exemption 155
FRAND licensing 156–157
fraudulent patents see abusive filing of IP
rights
free movement of goods principle 439–442
free patent release 324–325
French, Robert Shenton 64–67, 73, 75–76, 88–89, 93, 97
FTC v. Actavis 457–459
Fuel Oils/Exxon case 218
function-limited protection 7, 37, 152, 183–184
Gageler, Stephen 68–71, 76, 97–98
gene and DNA fragments see DNA sequences
gene patents
gene as ‘discovery’ or ‘invention’ 360
litigation vs. models based on 332–333

Duncan Matthews and Herbert Zech - 9781783479450
Downloaded from Elgar Online at 06/08/2019 02:48:23PM
via free access
source information required in China 358
university vs. private firm strategies 267
see also DNA patents; human genes, patenting
General Agreement on Tariffs and Trade (GATT) 369, 428–429
generic drugs
access in Kenya 396–399, 402–406
definitions 3–7
difficulty distinguishing from counterfeits 403
impact of pipeline patents on 344
manufactures in South Africa 410–411, 415
patent settlements between originator and generic companies 453–455
potential impact of ACTA and IMPACT 399
prices 3–4, 12, 339, 426, 436, 459, 463
storage allowed by Indian patent statute 377
see also biosimilars; follow-on biologics; medicine; pay for delay agreements
generic seed development after transgenic patent expiration 192–196
genetically modified crops see transgenic plants
Genetic Event Marketability & Access Agreement (GEMAA) 194–195

genetic resources see gene patents; plant genetic resources
Genetic Technologies Limited, claim for non-coding DNA rejected 78

genome sequencing 197, 209, 211–213
see also Human Genome Project (HGP)
Germany
breeder’s exemption 155
court cases on chemical compounds 29–30
product-by-process claims 218
Supreme Court 443
unfair competition law 475–478
Geron Corporation 247, 248
Geyer, Alexandre 338
Gilsenan, Rebecca 92, 100–102
Glivec® see Novartis
Global Bio-Collecting Society (GBS) 322
Glucosamylase case 362

glucosinolate 133, 138, 143
glyphosate see Roundup Ready® (RR)
Gold, E. Richard 94, 98, 279
Golden Rice technology/pool 311, 314–315, 334
good faith principle 13, 195, 432, 468–469, 474, 480
Gordon, Michelle 71–73, 76, 98
Grabowski, Henry G. 111
Graham v. John Deere 166
Greenovation 314–315
GreenXchange 320
grey market goods see parallel imports
Grogan, Paul 81, 100
Haanes, Elizabeth J. 18
Hargreaves, Ian 338
harmonization
Brazilian patent law changes needed to achieve 346
JPO harmonization efforts with USPTO and EPO 380–381, 384–386, 393–394
questioning of its importance 99–100
resistance of developing countries to 369–372, 379
technology transfer regulations 450
through EU Directives 444–446
see also Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
Harvard Oncomouse case 94, 272, 281–282
harvested materials, variety constituents vs. 220–221
health
compulsory licenses for public health needs 418–420
concern over impact of gene patenting on clinical care 95
focus of Kenya Industrial Property Act 397–398
IP rights vs. right to 100–102, 395–396, 402, 405, 424–427
long exclusivity periods and 111–112, 115
patent clearinghouses 317–318, 321
patents equated with 370
potential impact of diagnostic patents on 15–17
research projects studied in FP7 235
South African right to 408
TRIPS public health related flexibilities 408–410, 412, 415–416, 417, 422, 427–428
see also HIV/AIDS; medicine
Heckscher, Zahara 102–103
Heller, Michael A. see Eisenberg, Rebecca
hematopoietic stem cells in cord blood 254
Herceptin™ 16
Herder, Matthew 290–291
High Court of Australia see Australia; D’Arcy v. Myriad Genetics, Inc.
HIV/AIDS
efavirenz treatment 350–351, 426
pipeline patents on drugs 344
South Africa 409–411, 415
Thailand compulsory licenses for drugs 426, 427
homology 151, 362–363, 367
Ht event, definition 179
human embryonic stem cells (hESC) definition 245
Japan Patent Office (JPO) vs. MEXT guidelines 390–391
not patentable in China 358
see also stem cell research
human genes, patenting advancement of clinical care threatened by 95
Australia’s approach vs. US and EU 89–98 changes internationally 26–29, 35–40 consequences of Myriad and its progenies 54–55
description of technology 43–45 exclusion of human embryos from research 239
history of patentability in US 45–47 international debate 88–89, 304–305 international harmonization 99–100 JPO treatment as chemical compounds 385
desirability of primers and probes 50–53 stricter patent-eligibility under Mayo and Myriad 47–50
US Supreme Court curtailment of patentable subject matter 41–43 wrong as matter of legal principle 84
see also DNA patents; ethics
human Genome Project (HGP) 280–281, 285–288
Human Genome Sciences Inc. v. Eli Lilly & Co. 97
human intervention as key to patentability 27–28, 58
human stem cells see human embryonic stem cells (hESC); induced pluripotent stem cells (iPSCs); stem cell patents; stem cell research hybrid varieties, patentability challenges 138–139
Hyman, David A. 258
IFN- case 30
Imidazoline case 30
imports and patent protection
Kenya 396–398, 401–403
patentability of imported soy meal 183–184 for resale in India 377–378
IMS Health case 480
incentives to invent and disclose as justification for US patent system 261
India conforming differently 370, 371–378, 405
cost of generic drugs 344
Intellectual Property Appellate Board 378–379
patenting of transgenic crops 184 polymorph patenting in 345
public non-commercial use 343
Indian Patents Act, Section 3(d) 374
induced pluripotent stem cells (iPSCs) definition 245–246
patents increasingly directed at iPSCs technology 249–250
Yamanaka’s research 380, 383, 394
see also stem cell research
industrial applicability
Brazil 339–340, 345, 346, 347, 353
BRCA testing economically useful 63
criterion in Biotech Directive 31–32
DNA inventions without specific utility fail 386
inventions must belong to ‘‘useful arts’’ 21–22 of an isolated nucleic acid must be disclosed 97
JPO, USPTO and EPC requirements 389–390
types of claims accepted or rejection on basis of 416
utility of inventions in China 357, 359–360
utility of inventions in India 373
see also commercialization
information and communication technology (ICT), patent pools in ICT sector 313
information clearinghouses 315–316, 317
inherency doctrine, Japan vs. US 391–393
innovation disputed effect of patent pools on 329–331
effect of patents on 42–43, 66–67, 73
effects of exclusivity on 111–112
goal shared by IP and competition law 472
imped在日本 imposed by US DNA patents 386
see also anti-commons hypothesis; US Bayh-Dole Act
Institute of Patent and Trade Mark Attorneys of Australia 83
intellectual property (IP)
beginning of new era 279
diversity in the era of harmonization 369–370
international investment law and 429–431
IP rights vs. right to health and medicine see health
legislative history in South Africa 412–413
need for balanced and development oriented
IP system 213
need for well-tailed IP strategies 332
in R&D agreements see research and
development (R&D) agreements
see also abusive filing of IP rights; European
Union (EU); plant genetic resources;
individual countries by name
interchangeables and biosimilars 108
International Centre for Settlement of
Investment Disputes (ICSID) 432–433
International Expert Group on Biotechnology,
Innovation and Intellectual Property 279
international investment law see investor-state
dispute settlement (ISDS)
international law
breaches vs. FET 434–436
supremacy over national legislation 432
International Law Commission (ILC) 433
International Licensing Platform (ILP) –
Vegetable 156–157, 318–319, 320, 324,
328, 334
International Medical Products Anti-
Counterfeiting Taskforce (IMPACT)
399–400, 403
international non-proprietary name (INN)
disclosure 416
International Treaty on Plant Genetic
Resources for Food and Agriculture
(ITPGRFA) 205–211, 212
International Union for the Protection of New
Varieties of Plants (UPOV) 121–131, 164,
165, 206
introns 182
inventiveness requirement
Anvisas understanding of 348
China 356, 357, 360, 366–367
Commissioner’s proposals subject to 80
discovery subject to 48, 346
EPO provisions regarding technicality 32–35
higher inventive/non-obviousness standard
32–35, 36–37
India 373–374
inventive concept 52
Japan and US 387–389, 391–393
Myriad case 68–70
Sequenom case 23
South Africa 416
under Swiss law 10
investor-state dispute settlement (ISDS)
compulsory licenses vs. 424, 430–431
provisions in TPP 102
TRIPS law not yet applied to ISDS
proceedings 432–436
IP Australia 77–84
isolated nucleic acids
Australian High Court on 28
industrial applicability 97
as product of nature 91–92
see also BRCA genes and testing; DNA
sequences
Jacobson, Mervyn 78
Japan
Basic IP Law 382
‘Biotechnological Invention Guidelines’
386–387
IP Strategy Headquarters 382
Japanese Patent Act (JPA) 382
JPO harmonization efforts with USPTO and
EPO 380–381, 384–386, 393–394
life science industry and research 380–384
Ministry of Education, Culture, Sports,
Science and Technology (MEXT) 390
patentability conditions 386–393
patentability of diagnostic methods 25
Science and Technology Basic Law 381
Japan Agency for Medical Research and
Development (AMED) 384
Japan IP High Court 384
Japan Ministry of Economy, Trade and
Industry (METI) 380, 382, 383
Japan Ministry of Health Labor and Welfare
(MHLW) 382
J.E.M. Ag Supply, Inc. v. Pioneer Hi-Bred
International, Inc. 163, 166, 181
Jensen, Kyle 276–277, 305–306
Johnson & Johnson and Sandoz/Novartis
(fentanyl case) 461
joint inventions in R&D agreements 298–299
Jolie, Angelina 19
judicial estoppel, Monsanto’s statements
binding as matter of 190–192
Kaletra, licensing in Thailand 426
Kenya
Anti-Counterfeit Act 2008 398–402
Anti-Counterfeit Agency (ACA) 401, 406
implications and implementation of P.A.O.
judgement 405–407
Industrial Property Act to comply with
TRIPS 396–398
influence over laws of East African
Community 396
Kenyan Industrial Property Office (now
Institute) (KIPI) 396
right to health vs. IP rights 395–396, 402–405
Kenya Association of Manufacturers (KAM) 400–402, 407
Kenya Coalition for Access to Essential Medicine (KCAEM) 396–398, 406
Kenyan AIDS Law Project 403, 406–407
Ketlaphela initiative 410–411
Kiefel, Susan 64–67
King, Catherine 85–86
King, Mary-Claire 91
Kirin-Amgen Inc. v. Hoechst Marion Roussel Ltd 96–97
know-how 293, 295–296, 297, 301, 302, 303
KSR Int’l Co. v. Teleflex, Inc. 165–166, 171–175, 177, 253–254, 386
Kubin case 462
Lab Corp. v. Metabolite Laboratories 47–48
Lampe, R. 329–330
law of nature see nature-based products
lead compound/unexpected results methodology 166–172
legal qualifications in R&D agreements 294
legitimate expectations 430, 431–436
Lemley, Mark 283–284, 291
Lens initiative 315–316
Librassay (licensing supermarket) 320, 321, 334
licenses/licensing
absence or presence of a clearinghouse and 316
absence or presence of a patent pool and 313
draft Public Licence for sharing germplasm information 212
in patent pools 312
of patents relating to native traits 156–157
public patent licenses 320
in R&D agreements 295–296, 301–303
see also collaborative licensing mechanisms; compulsory licenses
Linn, Richard 23–24
Lisbon Treaty 233–234
Lists of Licensed Biological Products with Reference Products Exclusivity and Biosimilarity or Interchangeability Evaluations (Purple Book) 108
litigation
impact on business strategies 332–333
nuisance or trespass claims as way to avoid transgenic contamination 190–192
and prosecution of patents 299
regarding transgenic plants 180–181
Lo, Dennis 22–23
Lonza Ltd. 410–411
Losec see AstraZeneca v. Commission
Louisiana Wholesale Drug Co. Inc. v. Bayer AG 457
Lundbeck A/S and Lundbeck Ltd. v. EU Commission 460–461, 467
MacPherson, Sandra 95
Magill case 480
mail-box mechanism 372, 379
maintenance of patents 299
man-made mutations, plants with, definition 133
manner of manufacture requirement in Myriad case 60–62, 64–70, 72, 75–76
marker-assisted selection 136–137
market entry delay see pay for delay agreements
market exclusivity see exclusivity
market power of Myriad Genetics, Inc. 93–94
material transfer agreements (MTAs) 259–260, 284, 288–289
see also Standard Material Transfer Agreement (SMTA)
matter and process claims 15
Maurice Blackburn Lawyers 82–83
Mayo Collaborative Services v. Prometheus Laboratories Inc. 17–19, 23–24, 38, 42, 48–49, 51, 251–252, 259
McLaren, Oscar 82–83
medical biotechnology, evidence of patent thicket 310
medicine
access in Kenya 395–399, 401–406
competition law and access to 420–421
compulsory licenses make access affordable 436
equitable access 81, 371
impact of pipeline patents on costs 344
Japan’s life science focus on medical sciences 381
medication method for antibiotics invalid in China 364–365
practitioner immunity from infringement 389–390
regenerative 383, 391
US Preserve Access to Affordable Generic Act 456–457
WTO and access to 371
Index

see also generic drugs; health; pharmaceutical industry
Medicines Patent Pool (MPP) 314, 326, 328, 334
Melamed, A.D. 327
Merk see efavirenz
Merck & Co. Inc. v. Stephar BV and Petrus Stephanus Exler 443–444
Merges, R.P. 308, 327
method claims
breeding technologies of plants 162, 163, 175
for patenting diagnostics 19, 20, 24, 51–52, 53, 55, 90
pharmaceutical method claims 382
minimum access standards see access to genetic resources and benefit-sharing (ABS)
modafinil 460
molecular markers, national variations regarding patentability 151
see also biomarker-based diagnostic tests
Monotti, Ann 65
Monsanto Canada Inc. v. Schmeiser 94–95
Monsanto Corporation 180, 189–190
Monsanto Tech. LLC v. Cefetra BV 32, 36, 183–184
Monsanto Tech. LLC v. Controller of Patents & Designs 184
Monsanto v. Cargill 153
Moser, P. 329–330
Mowery, David C. 262, 263, 264–265, 288–289
MPEG LA (administrator of patent pools) 321
Multilateral System (MLS) of ABS 205, 207, 208–209
Murray, Fiona 270–272, 276–277, 289, 305–306
mutually agreed terms (MAT) 200–201, 203–204
Myriad Genetics, Inc. 19–21, 77, 78–79, 281
see also D’Arcy v. Myriad Genetics, Inc.

Nagoya Protocol on ABS 201–205
Nairobi High Court, unconstitutionality of anti-counterfeiting legislation 395
Namibia, proposal regarding benefit-sharing 209
National Research Council (NRC) 269, 272, 291
National Research Development Corporation v. Commissioner of Patents (NRDC) 61, 62–63, 72, 91
national ron 87
National Stem Cell Bank 249
native traits, plants with categories of typical claims 136–137
claims to native trait sequences 151
claims to progenies 152–154
definition 132–133
economic impact of patents 134, 136
EPO patents 214–218
limits to patent coverage 221–225
obtainable vs. obtained traits 154
scope of claim supported by a deposit 150–151
scope of protection 215, 218–221, 224–225
summary and outlook for patents in the EU 158–159
nature-based products
isolated nucleic acids as product of nature 91–92
Japan considers statutory inventions 387–388
Japan vs. US 393
naturally occurring genes not patentable 46, 182
US, Australia, and EU patentability 151
see also artificial state of aff airs requirement
Netherlands
breeder’s exemption 155, 156
fentanyl case 461
Nettle, Geoffrey 68–71, 76, 97–98
Neuberger, David, Lord 97
NEUROSTEMCELL project 240–241
new chemical entity (NCE) exclusivity 106
new drug application (NDA) 106–107, 455
new forms of known substances and new uses drug combining vs. compound preparation 366
eligibility in Japan vs. US 387–388
Indian Patent Act vs. US CAFC 374
new uses as discoveries, not inventions 346–347
patent exclusion in South Africa 415–416
polymorph patenting 345–346
stem cell patents 244
New Zealand, no impact of TPP on pharmaceutical law 115–116
Nexavar Licensed in India 374–377
Ngugi, Mumbi 403, 404, 406
Nicholas, John Victor 60–62, 74, 89–90, 96
Nicol, Dianne 79
NIH Knockout Mouse Project (KOMP) 282–283
non-commercial purposes, private use of plants 129
non-extension of the patent term 342–343, 345, 374
see also stacking/evergreening
non-obviousness
Brazil 339, 340, 341, 342, 345–346, 353

Duncan Matthews and Herbert Zech - 9781783479450
Downloaded from Elgar Online at 06/08/2019 02:48:23PM
via free access
breeding methods and 175–177
India’s requirement more stringent than in US 373–374
Japan vs. US 386, 391–393
non-obvious plants 160–166
patent law on 253–254
requirements of US patent law 284
standard applied to plant varieties 165–175
vulnerability of non-transgenic corn varieties 177–178
non-transgenic plants, EU patenting definitions 132–134
farmers’ exemption 156
licensing 156–157
plant varieties covered by patents 135
research and breeders’ exceptions 154–156
see also native traits, plants with
North American Free Trade Agreement (NAFTA) on breaches of international treaties 435
Novartis
Imatinib Mesylate (Glivec®) 344, 374, 416, 426
Sandoz/Novartis 109–110, 461
novelty requirements
Brazil 339, 340, 341–342, 344, 345–346, 353
China 356, 357, 360
EPO leading cases 10–11
of genes in China 360
increased difficulty meeting 36
India’s definition includes worldwide prior art 373
inventive step in Japan and US and 391–393
plant DNA sequences satisfy 133
of plant varieties 123, 126, 146–147
South Africa 416
under Swiss law 9–10
Novozymes Co. v. PRB 362–363
Nungesser v. Commission 446, 449
obtainable vs. obtained traits 154
obviousness analysis see non-obviousness
obvious to try theory 173–175, 253–254
Ochiai, In re case 176
O’Farrell, In re case 174
One of Us 230–231
open innovation 330–331
openness required by patent pools 327–329
Orange Book 106, 108
Organic Seed Growers and Trade Ass’n v. Monsanto Co. 189–190
Organic Seed Growers and Trade Association (OSGATA) 189–190
originator manufacturers 105–107, 114
ovarian cancer see BRCA genes and testing
overlap of patents 241, 269, 298, 308, 309–310, 323–324
parallel imports
contractual restrictions 449–450
definition 439
of drugs in Kenya 398–400
patent rights 444–446
plant variety rights 445–447
principle of exhaustion of rights 442–448
principle of free movement of goods vs. 439–442
trademarks 439, 447–448
Parke, Davis v. Centrafarm 441–442
Parke, Melissa 84–85
Partnership Hub see WIPO Re:Search
patentability
conditions in Japan vs. US 386–393
criteria in South Africa 415–416
exceptions consistent with TRIPS 137
exceptions for essentially biological processes 139–146
exceptions for plant varieties 138–139
requirement for written description and enablement 147–150
requirements and patent quality in Brazil 339–341
requirements in China 364–365
substantive conditions for 470
see also best mode of invention execution; disclosure; industrial applicability; inventiveness requirement; non-obviousness; novelty requirements
western standards embraced by India 373–374
patent aggregators 323
patent canalization 290–291
patent clearinghouses
concept 315–317
life sciences 317–322
see also collaborative licensing mechanisms;
patent pools and clearinghouses
Patent Cooperation Treaty 470
The Patent Crisis and How the Courts Can Solve It (Burk and Lemley) 283–284
‘patent dance’ 12–13
patent deposits 148–150, 151–152, 164, 217, 218
patent-eligibility see patentability
patent examination
draft guidelines for Australia 84
system needed in South Africa 412, 416
patent holdup 325
Index 497

patent pools
concept 312–313
life sciences 313–315
see also collaborative licensing mechanisms
patent pools and clearinghouses
changing institutional design 325–329
changing objectives 323–325
characteristics of life science organizations 334
impact on innovation 329–331
patents
application, first ownership and assignment 297–298
bilateral agreements 351–352
classical view 238
covering EU plant varieties 135
debate life sciences sector 304–306
drug safety examination delays by Japan’s Japan MHLW 382
economic impact on native trait plants 134, 136
EU harmonization through directives 444–446
examination vs. regulation of 422–423
exclusivity vs. 111
few registered by South Africans 413
growth factors 307–308
joint inventions 298–299
none for GM varieties marketed in Europe 134
probabilistic property rights theory and 463–465
in R&D agreements 297–299
see also biosimilars; diagnostics, patenting; human genes, patenting; pay for delay agreements
Patents, Human Rights, and Access to Science (Plomer) 73–74
patent settlement agreements see pay for delay agreements
patent term extension 463–464
see also non-extension of the patent term
patent thickets
concept 308–309
impact on research 84–85
not really a problem in the life sciences 331–332
vs. patent overlap 310
pools and clearinghouses as response to emerging 323–325
stem cell technology 250
pay for delay agreements
anti-competitive criteria 462–463, 466
anti-competitive potential 451–453, 466–467
elements 453–454
patents and probabilistic property rights theory 463–465
potential infringement of the patent 465, 467
relevance of competition law 454–456
under US antitrust law 456–459, 466–467
peppers, seedless, patent claim 216
Perindopril case 462
Perrett, Graham 85
Personalized Health Care (PHC) 16–17
Peru, abbreviated market approval 115
pharmaceutical industry
attempts to protect test data 349–350
Brazilian patents and patent reform 338–339
farmers’ lobby vs. 370
Japan 382–384
lobbies for and against patent reform 354
pipeline patents 344
South Africa 397, 410–413
see also medicine
pharmaceutical method claims only eligible method claims in Japan before 1976, 382
Pharmaceutical Research and Manufacturers’ Association of Thailand (PReMA) 427–429
Pharmaceutical Sector Inquiry/Pharma Sector Inquiry 451, 459–462, 477
Pharmalingcising 317
Pharmastem Therapeutics, Inc. v. Viacell, Inc. 254
Philip Morris v. Australia/PM Asia 431, 432
physical phenomena unpatentable 46
Phythophthora root rot resistance 169
Pink Hope 100
PINTO database 134, 159
pipeline patents (revalidation patents) 344–345
plant breeders’ rights system, patent system vs. 147
plant-derived product claims 137
plant genetic resources
background 197–198
CBD and ABS 199–205
farmers’ rights 210–211
food security, agro-biodiversity conservation and plant IP 198–199, 205–207
global open genome sequence data framework for sustainable development 211–212
need for balance and development-oriented IP system 213
Plant Genetic Resources for Food and Agriculture (PGRFA) 205–211
plant innovations protection limitations on 129–131
TRIPS 121
UPOV 121–131
plant product-by-process, definition 163
plant production, breeding vs. 141–142
plants, non-obvious see non-obviousness
plants, transgenic see transgenic plants
Plantum (Dutch breeders association) 134
plant varieties
Community Plant Variety Regulation (CPVR) 445–447
denomination 126
not patentable in China 357–358
patent-claiming strategies 162–163
patent protection vs. PVP 178, 223
see also native traits, plants with
plant variety protection (PVP) see
Biotechnology Directive 98/44/EC; plant varieties
Plant Variety Regulation 2100/94
breeder’s exemption 223–225
scope of protection compared with Biotech Directive 220–221
Plavix, licensing in Thailand 426
Plomer, Aurora 73–74
pluripotent stem cells (iPSCs) see induced pluripotent stem cells (iPSCs)
Polymerase Chain Reaction (PCR) 46, 53
polymorph patenting 345–346
Potrykus see Golden Rice technology/pool
practical excluadibility 280–281, 284
practical use see industrial applicability
pre- and post-solution activities 18–19, 24
preemption, principle of 23, 49–53
pre-grant opposition see patent oppositions
 prenatal genetic testing 22–24, 53–54
Prentice, Jane 87
presumptive patent ownership, and US funded research 261, 291–292
primers, DNA
definition 45
patentability 50–51, 52, 54–55
prior art
bacterial cold shock proteins 184
in chemical compound case law 167–168, 392
in plant variety protection 169–177
product-by-process claims vs. 166
prior informed consent (PIC) 200–201, 203–204
probes
definition 45
patentability 51
patent eligibility 51–53
problem-specific tools see research process and matter claims 15
processes of analysis claims 137
production methods, methods of selection vs. 142
progenies of protected plants 152–153
Prometheus Laboratories see Mayo Collaborative Services v. Prometheus Laboratories Inc.
proof of concept patents 274
propagation material 122, 445–447
proteins
patentability of 8, 361–363
synthesis 44
public 376
publications, licenses for 302–303
Public Intellectual Property Resource (PIPRA) 318, 323, 334
public non-commercial use 343, 419, 425
public participation in patenting process, India’s success 376–377
public statements, licenses for 303
Purple Book 108
quantitative trait locus (QTL) 139, 147
The Queen v. Jacobson (Sentence) 78
radish claim invalid, due to public samples 147
Rai, Arti K. 269
rapeseed 174–175, 187–189
Reaping the Benefits (NRC report) 269, 272, 291
reciprocity rule 328
recombinant proteins in stem cell research 246
Red Dove (Rote Taube case) 142
regenerative medicine inventions 383, 391
registration of IP rights 468, 472–473, 480
regulatory data protection see exclusivity
Relaxin/HOWARD FLOREY INSTITUTE decision 33
remuneration see compensation; equity and fairness
re-packaging provisions in EU trademark regulation 448–449
research
careful drafting of restrictions, 301
exemptions 154, 181, 417
genomic research tools 265, 277–279, 319–320
IP protection tools 233
R&D costs make biologicals most expensive drugs 6
subject diversity 289–290
research and development (R&D) agreements
background IP 295–296
evaluation and confidentiality 295
licensing and exploitation 301–303
object and legal qualification 293–294
ownership of foreground IP 296–300
research cooperation, contract research vs. 293–298, 301
revalidation patents see pipeline patents
(reverse validation patents)
reverse payments see pay for delay agreements
Reynolds v. Herbert Smith & Co Ltd. 70
ribonucleic acid (RNA) 44–45, 246
Roundup Ready® (RR) 94–95, 179–180, 183, 187–189, 192, 196
Royal College of Pathologists 81–82
royalty collection clearinghouses 317, 322, 328
Rudd, Kevin 85–86
Sandoz/Novartis
fentanyl 461
Zarxio 109–110
saved seed exemptions 164, 181, 210
Schmeiser v. Monsanto Canada Inc. 187–189, 191
science
advancement of knowledge 235, 236, 241
chilling impacts of patents on basic 232
collaboration among researchers 289–290
US patent systems goal to promote progress 246
Science Commons see Biological Materials Transfer (BMT) Project
seed companies, securing of utility patents 163–165
seed product-by-process, definition 163
seed-saving exemption 164
Severe Acute Respiratory Syndrome (SARS) corona virus pool 314
sewing machine patent pool 313, 329–330
Shapiro, C. 308
Sherman, Brad 76, 99–100, 101
shock tolerance gene 184
Sigco Research, In re case 170–171
Silva, Graziano da 209
Single European Act (SEA) 233
small molecule medicines, exclusivity in US 105–107
social function of intellectual property 405
social response bias 266–267
Solvay Pharmaceuticals 457–458
South Africa
challenges by pharmaceutical manufacturers 397
competition related TRIPS flexibilities 420–422
compulsory licenses 417–420
Department of Trade and Industry (DTI) 412, 422–423
exhaustion of rights, general exceptions to patent rights 416–417
Industrial Policy Action Plan 410
legislation and regulations affecting life sciences 408–409, 411–413, 422–423
Medicines and Related Substances Control Act 416–417
patentability criteria 415–416
patent disclosure requirements 416
patent oppositions 413–415
patent procedure 413–414
Patents Act 411, 412, 413, 415–420, 422–423
public health and access to health technologies 409–411
South African Competition Act 421
sovereignty
over genetic resources 199–202, 207, 212
over patent systems under TRIPS 369, 379
as rhetorical strategy 401
soybeans
RR crops 180, 192, 196
RR soy meal exported from Argentina into Netherlands 183–184
variety claim 169–170
Spain, public non-commercial use 343
Special 301 mechanism see US Trade Representative (USTR)
Speevak, Marsha 95
stacking/evergreening
generic copies/combining of RR trait 192
India's restriction on evergreening or 374
likely to lead to new legal battles 196
seeds containing traits from multiple companies 195
standardized licenses clearinghouses 316–317, 319–322, 328
Standard Material Transfer Agreement (SMTA) 205, 207–209, 212
Statute of Monopolies 1624 (Australia) 60, 63, 65, 70, 72, 73, 74, 98
statutory invention (Japan) see inventiveness requirement
Stealing Fire (Haanes and Canaves) 18
stem cell patents
background in US 243–250
not available in China 358
patentability questions under US law 250–255
US legal battles and policy concerns 246–250
stem cell research
EU 229–232, 235, 239, 240–241
Japan 380, 383, 390–391, 394
stem cells, four types 244–246
see also embryonic stem cells (ESC); human embryonic stem cells (hESC); induced pluripotent stem cells (iPSCs)
Stern, Scott 270–272, 289
Stiglitz, Joseph 93–94, 337
Stocrin see efavirenz
storage of patented material 377, 412–413
Stott Despoja, Natasha 87
subbactam case 366
sunflower seeds, patent claims 170–171, 217, 222
supplementary protection certificates (SPCs) 463
surprising effect 374
Sweden, innovation systems compared with US 263–264
switching costs vs. royalties 329
Switzerland
compulsory licensing 159
patent law 7–10
seed marketing licensing 157
Switzerland-Thailand BIT 430, 432
Syngenta e-licensing 321–322, 324, 325, 328, 334
synthetic chemical compounds 29–30, 37–38
tagged primers 51
Takeda (Actos case) 458–459
technical breeding processes, essentially biological processes vs. 139–143
technology exchange clearings 316, 317–319, 328
technology transfer
EU Commission Technology Transfer Guidelines 465
EU regulations 449–450
route to patent assignment 264
territorial exclusivity 439, 446
test purposes not subject to protection 129
Tetraploid Chamomile case 149–150
Teva Cephalon (Modafinil case) 460
Teva Pharmaceutical Industries Ltd. 458
Thailand
compulsory licenses as TRIPS flexibility 424–427
Pharmaceutical Research and Manufacturers’ Association of Thailand (PhRMA) 427–429
Switzerland-Thailand BIT 430, 432
thiopurine drugs 17–18, 48
Thomas, Clarence, on patentability of cDNA vs. BRCA gene 90–91
Thomson, James 247, 254
Thursby, Jerry G. 268–269
Thursby, Marie C. 268–269
tomatoes
flavonol 216, 217
patent cases see Broccoli and Tomato cases
Torpharm, Inc. case 177
Toulmin, Stephen 258–259
trade see Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS); Doha Declaration on the TRIPS Agreement and Public Health; General Agreement on Tariffs and Trade (GATT); imports and patent protection; World Trade Organization (WTO)
Trade Mark Directive (TMD) 447–448
trademarks
Australia Plain Packaging Act claimed to impede PM Asia’s 431
examined only for absolute grounds for refusal 468
in R&D agreements 300
trade secrets
Celeria database 281
clinical data protected as 300
endangered by foreground information 238, 297
permission to disclose 301
traditional knowledge 201–204, 210, 213, 409
transgenic mice 94, 272, 281–283
transgenic plants
definition 133, 179
early litigation 180–181
inadvertent infringement/contamination 187–192
no patents in China for transgenic animals and 358–359
patent coverage 181–185
patent exhaustion 185–186
transgenic crop production 180
transitioning from patent to generic 192–196
Trans-Pacific Partnership (TPP)
concerns regarding health care access 101–103
exclusivity for biologics 113–116
Trastuzumab (Herceptin™) 16
Treaty on the Functioning of the European Union (TFEU)
parallel imports and 440–442, 444, 447, 449–450
patents and competition law 469, 474–475, 478, 480
pay for delay agreements and 455–456, 460–461
Trump, Donald, withdrawal of US from TPP negotiations 103, 116
tuberculosis (TB) 409, 411
Turnbull, Malcolm 86
Ullrich, H. 308
uncertainty in anti-counterfeit legislation 403, 405–406
for biosimilar and originator biologic companies 116–117
in high-tech patenting law 40
preventing legal 394
regarding biosimilar patent applications 10–11, 13–14, 110
UN Commission on International Trade Law (UNCITRAL) 432–433
UN Convention on Biological Diversity (CBD) 197–205, 208
see also plant genetic resources
undisclosed test data protection 349–350
unexpected results 166–172, 374
unfair competition law 475–478
UN Food and Agriculture Organization (FAO), International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA) 205–211
uniformity of plant varieties 124–125, 446
Unitary Patent Regulation (EU) 444
United Kingdom (UK)
Commission on Intellectual Property Rights (CIPR), 346, 348
Hargreaves Review of Intellectual Property and Growth 338
‘obtained by’ restrictions of product-by-process claims 218
public non-commercial use 343
United Nations (UN) see headings at UN
United States (US)
beneficial utility requirement 390
comparisons with patentability conditions in India 373–374
comparisons with patentability conditions in Japan 386–393
consequences of patent eligibility cases 54–55
fetal DNA in the mother’s serum 52–54
genome patent approaches compared with Australia 89–94
history of patentability of genes 45–47
isolated sequence non-patentable 151
legal cases on patenting diagnostic tests 17–25, 47–50
patentability of diagnostic methods 24
patents on primers and probes 50–53
restriction of product-by-process claims 218
struggling to establish public participation 377
unfair competition law 475
see also individual agencies
universities
comparative advantage in managing post-invention development process 291–292
impact of Bayh-Dole Act on research mission of 265–269
Mowery studies 288–289
role of Bayh-Dole in stimulating patenting by 260–265
upstream patenting impact on downstream innovation 269–279, 284
University of Arkansas, first generic RR soybean 196
University of Utah see Myriad Genetics, Inc.
unpredictable art rule 391–392
UN Sustainable Development Goals (SDGs) 213
upstream patenting, impact on downstream innovation 269–279
Uruguay Round of GATT, imposition of harmonization laws 369
US Barr Laboratories 457
US Bayh-Dole Act
access to materials and data and 280–289
debate over its impact on genetic research and development 256–260
mandate of 291–292
patenting impact on subsequent scientific collaboration and 289–291
provisions 256–257
research mission of US universities and 265–269
role in stimulating university patenting 260–265
upstream university patenting impact on downstream innovation 269–279
US Biosimilars Act 12–14
US Court of Appeals for the Federal Circuit (CAFC)
on cffDNA 22–24
Deuel and Kubin cases 386
first decision on abbreviated licensing for follow-on biologics 109–110
inherent limitations in obvious-to-try arguments 173–174
Myriad’s BRCA genes, patentability upheld 48–49
Myriad’s method claims invalid 52
patentability standards 373–374
rejected patent claims to mammals cloned
from somatic cells 78
reversed obviousness rejection 170–171,
176–177
subsidiary inquiries for chemical compound
claims 164–167
validated requirement for patenting new
forms of known substances 374
see also individual cases by name
US District Court for the Southern District of
New York
patentability of isolated DNA claims 20
on Takeda case 459
US Drug Price Competition and Patent Term
Restoration Act of 1984 (Hatch-Waxman)
105–107, 454–455
US Federal Food Drug and Cosmetic (FD&C)
Act 106, 107
US Federal Trade Commission (FTC)
on exclusivity periods 111–112
opposition to pay for delay agreements 452,
455, 456–458
on patenting new forms of know substances
338
US Food and Drug Administration (FDA)
12, 13, 14, 105–107, 192–193, 455, 457
ANDA 455
exclusivity for biologics 110–111
patent information required before drug
approval 12–13
US Manual for Patent Examination Procedure
374
US Medicare Prescription Drug and
Improvement Act 456
US National Institutes of Health (NIH)
filing EST patent applications 385
genome sequencing 286–288
guidelines on licensing genomic inventions
282–283, 284
Japanese AMED modeled after 384
US Patent and Trademark Office (USPTO)
disclosure requirements 470
harmonization efforts with JPO and EPO
380–381, 384–386, 393–394
need to make its obviousness analysis clear
177
obviousness rejections reversed by CAFC
176
parallel structure justification 165, 172
patentability of ‘isolated and purified’ DNA
sequences 46–47
PPH agreement with Brazilian Patent Office
351–352
utility patents directed to non-transgenic
plant varieties 160–161
US Patent Protection and Affordable Care Act
(PPACA) 107–108
US-Peru Free Trade Agreement (FTA) 115
US Plant Variety Protection Act (PVPA) 163,
164
US Preserve Access to Affordable Generic Act
456–457
US Price Relief, Innovation and Competition for Essential Drugs (PRICED) Act 112,
116
US Public Health Safety Act (PHSA) 107–108
US Sherman Act 454
US Supreme Court
computer programs not patentable 388
consumer vs. competition protection
466–467
curtailment of patentable subject matter
42
distaste for rigidity and mandatory formulas
165–166, 171–172
endorsed utility patents on plant varieties as
such 163–164
first decision on reverse payments 457–458
guidance on pay for delay agreements, EU
Commission vs. 452–453
isolated genes not patentable subject matter
20
New York Federal Court disagreed on
Takeda case 459
patentability of isolated DNA claims 20–21,
89–93
on pay for delay agreements 457–458
Prometheus claims invalid 18
utility and method of use patents for plant
varieties 181
see also Diamond v. Chakrabarty; Mayo
Collaborative Services v. Prometheus
Laboratories Inc.
US Trade Representative (USTR)
interpreting the TPP Agreement 116
Special 301 mechanism 372–373, 379,
426–427, 429
Utility Examination Guideline 47
utility patents, plant variety protection vs.
160–161, 163–165, 178
utility requirement for patent rights 254–255
see also industrial applicability
value for cultivation and use (VCU) 157
variety, plant
definition 122–123
essentially derived varieties 128–129
protection 123–128
variety as such/variety per se
application of obviousness methodologies 175–176
definition 163
Venter, Craig 286, 287
venture capital (VC), US vs. Japanese biotech firms 383
Verlinsky, Liza, on putting universities in charge of their inventions 291–292
Vienna Convention (VCLT) 144, 432, 433
Wainscoat, James 22–23
Walker Process Doctrine 474
Walsh, John P. 266–267, 272, 274, 285, 289
Walter and Eliza Hall Institute of Medical Research 83
Warthmann, Norman 212
Watson Pharmaceuticals 458
Waxman, Henry 116
Wicell (WARF) 248–249
Williams, Heidi 286–288
WIPO Re:Search 317–318, 334
Wirten, Eva Hemmungs 96
Wisconsin Alumni Research Foundation (WARF), stem cell patents 232, 246, 247–249

Wong, Ex Parte case 174–175
World Intellectual Property Organization (WIPO) see WIPO Re:Search
World Trade Organization (WTO) exclusion pertinent to biotechnology 184–185
India’s trepidation entering 373 possible impact on access to medication 371
trade regime, diversity and development paradigm 370–372
see also Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS); Doha Declaration on the TRIPS Agreement and Public Health; General Agreement on Tariffs and Trade (GATT)
writing mode of claims 363
see also best mode of invention execution
Xenophon, Nick 87
Yamanaka, Shinya 380, 383, 394
Zarxio 109–110
Ziedonis, Arvdis A. 289